Dirk Sibbing Shares a Recent ”Excellent Study” on Clopidogrel Versus Aspirin by Marco Valgimigli and Colleagues
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, reposted from Claudio Laudani on LinkedIn:
”Excellent study with clinically important results, especially in light of recent data at ESC 2025 in Madrid on hashtag#clopidogrel in secondary prevention for CAD patients after PCI. Valgimigli et al., Lancet 2025”
Read the full article here.
Article: Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
Auhtors: Marco Valgimigli, Ki Hong Choi, Daniele Giacoppo, Felice Gragnano, Takeshi Kimura, Hirotoshi Watanabe, Hyo-Soo Kim, Jeehoon Kang, Kyung Woo Park, Alf-Åge Pettersen, Mark Woodward, Deepak L Bhatt, Paolo Calabrò, Dominick J Angiolillo, Roxana Mehran, Young Bin Song, Joo-Yong Hahn
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
”Race has been shown to have a significant influence on clinical outcomes in patients with atherosclerotic cardiovascular disease.
However, the mechanisms behind such association are still poorly understood.
In this manuscript, we explored biological condition that may be responsible for such association, finding that among participant with atherosclerotic cardiovascular disease on chronic clopidogrel treatment, Black individuals have higher platelet reactivity (related to P2Y12 receptor activity) compared to non-Black individual.
In addition, we further confirmed the increased risk of MACE and myocardial infarction of Black individuals compared to non-black individuals among patients with coronary artery disease undergoing PCI.
These data highlight how further efforts are needed to reduce disparities between races, focusing on both healthcare access and biological process to guide the decision-making.”
Rad the full article here.
Article: Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants
Authors: Luis Ortega-Paz, Cameron D. Thomas, Claudio Laudani, Salvatore Giordano, Francesco Franchi, Kayla R. Tunehag, Fabiana Rollini, Selina Durukan, Joseph S. Rossi, Maryam Farahmandsadr, George A. Stouffer, Latonya Been, Ellen C. Keeley, Julio D. Duarte, Amber L. Beitelshees, Craig R. Lee, Larisa H. Cavallari, Dominick J. Angiolillo
Stay updated on all science in the field of coagulation with Hemostasis Today.
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden